Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109049 | 0.91 | EGFR (0.45) | AREGFRNPC1HPGDRAB9A | |
| SCHEMBL7113328 | 0.90 | EGFR (0.47) | AREGFRNPC1HPGDRAB9A | |
| SCHEMBL7111802 | 0.89 | SMN1; SMN2 (0.47) | EGFRNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1221632 | 0.88 | CYP19A1 (0.50) | AREGFRNPC1HPGDRAB9A | |
| SCHEMBL11671517 | 0.88 | AR (0.52) | AREGFRSMN1; SMN2BRD4SMPD1 | |
| SCHEMBL11880546 | 0.85 | NPC1 (0.46) | EGFRNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL7107169 | 0.85 | NPC1 (0.46) | EGFRNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6074414 | 0.84 | SLC40A1 (0.51) | ARNPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL11670129 | 0.84 | EGFR (0.44) | AREGFRNPC1HPGDRAB9A | |
| SCHEMBL11741662 | 0.84 | EGFR (0.44) | AREGFRNPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-07-24 | — | — | US | disclosed |
| US-6545053-B1 | Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2003-04-08 | — | — | US | disclosed |
| US-6187809-B1 | BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6172099-B1 | CARBAZOLE, DIBENZOFURAN, OR DIBENZOTHIOPHENE DERIVATIVES; DIETETICS, ANTIDIABETIC AGENTS; ANTILIPEMICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0997458-A1 | NOVEL TRICYCLIC COMPOUNDS HAVING SATURATED RINGS AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-05-03 | — | — | EP | disclosed |
| US-6037362-A | CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 2000-03-14 | — | — | US | disclosed |
| EP-0882707-A1 | NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-4024281-A | N,N-bis[2-(3-substituted-4-hydroxyphenyl)-ethyl or -2-hydroxyethyl]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1977-05-17 | — | — | US | disclosed |
| US-4021485-A | BRONCHOSPASMOLYTICS, ANTIPRURITICS, ANTIALLERGICS | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
| US-3933913-A | N,N'-bis[3-substituted-4-hydroxypheyl)-2-hydroxyethyl)]-polymethylenediamines | SMITHKLINE CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139475-A1 | Novel tricyclic compounds and drug compositions containing same | ADRB3, MC2R, NR3C1 | AR 46/4885EGFR 1053/4885NPC1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.